Ribociclib Real-world Treatment Patterns and Clinical Outcomes Among Women With HR+/HER2- Advanced or Metastatic Breast Cancer in France
- First Posted Date
- 2023-01-25
- Last Posted Date
- 2024-06-24
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 482
- Registration Number
- NCT05697146
- Locations
- ๐ซ๐ท
Novartis Investigative Site, Villeurbanne, France
Long-term Safety and Tolerability of Inclisiran in Participants With HeFH or HoFH Who Have Completed the Adolescent ORION-16 or ORION-13 Studies
- Conditions
- Interventions
- First Posted Date
- 2023-01-12
- Last Posted Date
- 2024-09-30
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 154
- Registration Number
- NCT05682378
- Locations
- ๐บ๐ธ
Excel Medical Clinical Trials LLC, Boca Raton, Florida, United States
๐บ๐ธIcahn School of Med at Mt Sinai ., New York, New York, United States
๐บ๐ธCincinnati Childrens Hospital MC ., Cincinnati, Ohio, United States
24 Weeks Double-blind Randomized Placebo-controlled Trial to Evaluate Efficacy, PK, Safety of LOU064 in Adolescents (12 - <18) With CSU and Inadequate Response to H1-antihistamine Followed by Optional 3 Years Open-label Extension and an Optional 3 Years Safety Long-term Treatment-free Follow-up
- Conditions
- Interventions
- First Posted Date
- 2023-01-10
- Last Posted Date
- 2024-11-19
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 100
- Registration Number
- NCT05677451
- Locations
- ๐บ๐ธ
Northshore University Health System, Glenview, Illinois, United States
๐บ๐ธAllergy and Asthma Specialist P S C, Owensboro, Kentucky, United States
๐บ๐ธSeattle Allergy and Asthma Rsch, Seattle, Washington, United States
Secukinumab (Cosentyxยฎ) Effectiveness in Axial Spondyloarthritis and Psoriatic Arthritis Patients Using Artificial Intelligence (SpAINET): Spanish Multicenter, Retrospective, Real World Evidence Study
- First Posted Date
- 2023-01-10
- Last Posted Date
- 2023-01-10
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 758
- Registration Number
- NCT05677542
- Locations
- ๐ช๐ธ
Novartis Investigative Site, Valencia, Spain
Long-term Extension Study of Ligelizumab in Food Allergy
- Conditions
- Interventions
- First Posted Date
- 2023-01-10
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 165
- Registration Number
- NCT05678959
- Locations
- ๐บ๐ธ
UCHealth Outpatient Pavilion, Aurora, Colorado, United States
๐บ๐ธAtlanta Allergy and Asthma Clinic, Marietta, Georgia, United States
๐บ๐ธAnn and Robert H Lurie Childrens Hospital of Chicago, Chicago, Illinois, United States
Real-World Assessment of Clinical Outcomes in Metastatic NSCLC Patients With MET Exon 14 Skipping Mutation and Brain Metastases Treated With Capmatinib
- First Posted Date
- 2023-01-09
- Last Posted Date
- 2023-01-09
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 68
- Registration Number
- NCT05675683
- Locations
- ๐บ๐ธ
18 Novartis Investigative Sites in the US, East Hanover, New Jersey, United States
A Study to Evaluate the Efficacy, Safety, Pharmacokinetics and Dosimetry of [177Lu]Lu-PSMA-617 in Chinese Adult Male Patients With Progressive PSMA-Positive mCRPC
- Conditions
- Interventions
- First Posted Date
- 2023-01-04
- Last Posted Date
- 2024-12-06
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 60
- Registration Number
- NCT05670106
- Locations
- ๐จ๐ณ
Novartis Investigative Site, Tianjin, China
Study Assessing the Efficacy and Safety of a Personalized Monotherapy Regimen of Brolucizumab in Patients With Symptomatic Macular Polypoidal Choroidal Vasculopathy
- Conditions
- Interventions
- First Posted Date
- 2022-12-28
- Last Posted Date
- 2024-04-17
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 160
- Registration Number
- NCT05666804
- Locations
- ๐ฐ๐ท
Novartis Investigative Site, Seoul, Korea, Republic of
An Open-label, Adaptive Design, Positron Emission Tomography Study in Healthy Male Participants to Characterize Receptor Occupancy by MIJ821 in the Brain
- First Posted Date
- 2022-12-28
- Last Posted Date
- 2024-04-01
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 10
- Registration Number
- NCT05666687
- Locations
- ๐ฌ๐ง
Novartis Investigative Site, Watford Road Harrow, United Kingdom
A Study Evaluating [177Lu]Lu-PSMA-617 vs. a Change of Androgen Receptor-directed Therapy in Taxane Treatment Naive Chinese Male Patients With Progressive Metastatic Castrate Resistant Prostate Cancer
- Conditions
- Interventions
- First Posted Date
- 2022-12-20
- Last Posted Date
- 2024-08-02
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 60
- Registration Number
- NCT05658003
- Locations
- ๐จ๐ณ
Novartis Investigative Site, Tianjin, China